Form 8-K · Current Report · Filed 2026-01-13
Revvity Announces Preliminary Q4 2025 Results and Upcoming J.P. Morgan Presentation
Revvity, Inc. announced preliminary financial results for the fourth quarter of 2025, projecting approximately 6% reported revenue growth and 4% organic revenue growth, leading to estimated Q4 revenue of $772 million. The company also expects full year 2025 adjusted earnings per share to exceed the upper end of the previously provided guidance of $4.90-$5.00. The full financial results will be released on February 2, 2026, with a conference call hosted by the CEO and CFO. Additionally, the CEO is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0000031791-26-000003
- CIK
- 0000031791
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$103.89
Next session
+7.3%
Since filing
+41.2%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
About Revvity Inc.
Revvity Inc. is a prominent company in the healthcare and biological sciences field, offering a comprehensive suite of solutions aimed at improving global health outcomes. The company's core focus lies in delivering innovative products and services that range from diagnostic tools to advanced analytical capabilities for life sciences research. Revvity serves a wide array of sectors including biotechnology, pharmaceuticals, and clinical diagnostics, providing essential tools and data analytics that aid in disease discovery, drug development, and health monitoring. The company's expertise in deploying cutting-edge technologies further reinforces its position as a critical enabler of scientific research and innovation. With its global reach and commitment to enhancing healthcare delivery, Revvity Inc. plays a pivotal role in advancing the capabilities of medical and scientific communities worldwide, driving progress in critical areas such as personalized medicine and preventive healthcare.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.